Title: To Study the Clinical Profile and Viral Markers (Hepatitis B and C) In Acute and Chronic Liver Disease
Authors: Dr Shivani Saini, Dr S.M. Garg, Dr Nitish Thakur
DOI: https://dx.doi.org/10.18535/jmscr/v5i2.122
Abstract
Background and Objective: Hepatitis B and Hepatitis C virus are endemic in India and have an aetiological role in acute hepatitis, 50-70% of which end up with chronic liver disease. Hepatitis Bis responsible for approximately 300 million cases of chronic liver disease worldwide and is the leading cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma worldwide. Hepatitis C is the major cause of transfusion transmitted non-A and non-B hepatitis and continues to be a major cause of liver disease throughout the world. As there are limited numbers of studies regarding this, the present study is undertaken.
Methodology: 50 patients selected using purposive sampling technique admitted in the Department of Medicine, Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, Ambala from the period of July 2014 to September 2016
Results: Fifty patients with liver disease were studied. Majority of patients were in mean age group of 41-60 years. Male to female ratio was 4.5:1. Majority of patients presented with abdominal distension, anorexia and jaundice. Majority of patients had abnormal liver function test. 34% patients had viral markers in the form of HBs Ag in 26% and Anti HCV in 8% cases.
Interpretation and Conclusion: Hepatitis B and C are the major causes of chronic liver disease.
Keywords: Hepatitis B; Hepatitis C; Acute hepatitis; Chronic hepatitis; Liver Cirrhosis, Hepato cellular carcinoma.
References
1. Bircher, Benhamoll, Intyre MC, Rizzetto, Rodes. Textbook of Hepatology. 2nd ed. Oxford Textbook of Clinical Hepatology Vol I.
2. Harrison’s Textbook of Internal Medicine.
3. Sherlock S, Dodey J. Diseases of liver and biliary system. 11th ed. Blackwell Scientific Publications; 2002.
4. Sleisenger and Fordtran’s Gastrointestinal and liver disease. 7th ed. Pathophysiology / Diagnosis / Management. Vol II.
5. Lurman A. Eine Icterus epidemic. Berl Klin Wochenschr 1885;22:P20-3.
6. Brandt LJ, Daun F, Friedmen LS, et al. Clinical practice of gastroenterology. II:P831-48.
7. Don G, Prince, Alfred M. Mechanism of disease: Hepatitis B virus infection – Natural history and clinical consequences. N Engl J Med 2004 Mar 11; 350(11): P1118-29.
8. Kottilil S, Jackson JO, Polis MA. Hepatitis B and Hepatitis C in HIV-infection.Indian J Med Res 2005 Apr;121:424-50.
9. Arora U, Mann A. Prevalence of Hepatitis B virus, Hepatitis C virus and HIV in patients of chronic liver disease in Amritsar. JIACM 2007;8(1):29-31.
10. Arora D, Sehgal R, Gupta N, et al. Prevalence of parenterally transmitted Hepatitis viruses in clinically diagnosed cases of Hepatitis. Ind J Med Microbiol 2005;23:P44-7.
11. Yamada. Chronic Hepatitis B viral infection. Chapter 107. 4th ed. In: Textbook of Gastroenterology; 2003.
12. Chowdhury A. Community based epidemiological study of Hepatitis B virus infection in India. Hep B Annual 2004;1:P17-24.
13. Chu CJ, Hussain M, Lok ASF. Hepatitis B virus genotype B is associated with earlier HBe Agserocon version compared with Hepatitis B virus genotype C. Gastroenterology 2002;122:P1750-62.
14. Thomas, David, Astenborski, et al. Natural history of Hepatitis C virus infection: Host, viral and environmental factors. JAMA 2000 Jul 26;284(4):P450-6.
15. Koizumi K. Diversity of quasi species in various disease stages of chronic Hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995;P22:30.
16. Bennet NJ, Domachouske J. Hepatitis C. e medicine; 2007 Aug 21.
17. Zuckerman AJ (1996). Baron S; et al., eds. Hepatitis Viruses. In: Baron's Medical Microbiology (4th ed.). Univ of Texas Medical Branch. ISBN 0-9631172-1-1
18. "WHO | Hepatitis B". www.who.int. Retrieved 2015-07-12.
19. Locarnini S (2004). "Molecular virology of hepatitis B virus". Semin. Liver Dis. 24 (Suppl 1): 3–10. doi:10.1055/s-2004-828672. PMID 15192795.
20. Howard CR (1986). "The biology of hepadnaviruses". J. Gen. Virol. 67 (7): 1215–35. doi:10.1099/0022-1317-67-7-1215. PMID 3014045.
21. Van Hemert FJ, van de Klundert MA, Lukashov VV, Kootstra NA, Berkhout B, Zaaijer HL (2011). "Protein X of hepatitis B virus: origin and structure similarity with the central domain of DNA glycosylase". PLoS ONE. 6 (8): e23392. doi:10.1371/journal.pone.0023392. PMC 3153941 . PMID 21850270.
22. Lin B, Anderson DA (2000). "A vestigial X open reading frame in duck hepatitis B virus". Intervirology. 43 (3): 185–90. doi:10.1159/000025037. PMID 11044813.
23. Osiowy C, Giles E, Tanaka Y, Mizokami M, Minuk GY (2006). "Molecular evolution of hepatitis B virus over 25 years". Journal of Virology. 80 (21): 10307–14. doi:10.1128/JVI.00996-06. PMC 1641782 . PMID 17041211.
24. Zhou Y, Holmes EC (August 2007). "Bayesian estimates of the evolutionary rate and age of hepatitis B virus". J. Mol. Evol. 65 (2): 197–205. doi:10.1007/s00239-007-0054-1. PMID 17684696.
25. Paraskevis D, Magiorkinis G, Magiorkinis E, Ho SY, Belshaw R, Allain JP, Hatzakis A (2013). "Dating the origin and dispersal of hepatitis B virus infection in humans and primates". Hepatology 57 (3): 908–16.
doi:10.1002/hep.26079. PMID 22987324.
26. Op De Beeck A, Dubuisson J; Dubuisson (2003). "Topology of hepatitis C virus envelope glycoproteins". Rev. Med. Virol. 13 (4): 233–41. doi:10.1002/rmv.391. PMID 12820185.
27. Kato N (2000). "Genome of human hepatitis C virus (HCV): gene organiz-ation, sequence diversity, and variation". Microb. Comp. Genomics. 5 (3): 129–51. doi:10.1089/mcg.2000.5.129. PMID 11252351.
28. Jubin R (2001). "Hepatitis C IRES: translating translation into a therapeutic target". Curr. Opin. Mol. Ther. 3 (3): 278–87. PMID 11497352.
29. Berry KE, Waghray S, Mortimer SA, Bai Y, Doudna JA; Waghray; Mortimer; Bai; Doudna (October 2011). "Crystal structure of the HCV IRES central domain reveals strategy for start-codon positioning". Structure. 19 (10): 1456–66. doi:10.1016/j.str.2011.08.002. PMC 3209822 . PMID 22000514.
30. Dubuisson J (2007). "Hepatitis C virus proteins". World J. Gastroenterol. 13 (17): 2406–15. doi:10.3748/wjg.v13.i17.2406. PMC 4146758 . PMID 17552023.
31. Ming-Ling Chang Yun-Fan Liaw; Hepa-titis B flares in chronic hepatitis B: Patho-genesis, natural course, and management DOI: http://dx.doi.org/10.1016/j.jhep.2014.08.033
32. Daniel J. Felmlee,1,2Mohamed Lamine Hafirassou,1,2Mathieu Lefevre,1,2Thomas F. Baumert,1,2,3,* and Catherine Schuster1,2,* Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease Published online 2013 May 22. doi: 10.3390/v5051292
33. Viral Hepatitis- The Silent Disease Facts and Treatment Guidelines Directorate General of Health Service, Ministry of Health & Family Welfare Government of India
34. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327:1906-1911. 13.
35. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G, et al. Long-term fellow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273-281.
36. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
37. Fattovich G, Giustina G, Gegos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterol 1997; 112: 463-472.
38. Niederau C, Lange S, Heintges T, Erhars A, Buschkamp M, Hueter D, Nawrocki M, et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998; 28:1687-1695. 20. Hu K-Q, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29:1311-1316.
39. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 240:1228-1233.
40. Jamal MM, Son A, Quinn PG, Wheeler DE, Arora S, Johonston D. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwest United States. Hepatology 1999; 30:1307-1311.
41. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype-1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32:91-96.
42. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, et al. The natural history of hepatitis C virus infection. Host, viral, and environmental factors. JAMA 2000; 284:450-456
43. Cacciola I, Pollicino T, Aquadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341:22-26.
44. De Maria N, Colantoni A, Friedlander L, Leandro G, Faruki H, Van Thiel DH. The effect of prior HBV infection on the ene-of-treatment response (ETR) to high dose interferon in individuals with chronic hepatitis C. Hepatology 1999; 30:195A.
45. Ulah N, Siddiqui FA, Naylor PH, Kinzie JL, Ehrinpreis MN, Peleman RR, Mutchnick MG. Presence of hepatitis B virus core antibodies (Anti-HBc) in chronic hepatiti C patients is predictive of a decreased end of treatment response (ETR) to interferon. Hepatology 1999; 30:195A.
46. Irshad M1, Acharya SK. Status of hepatitis viral markers in patients with acute and chronic liver diseases in northern India. Intervirology. 1994;37(6):369-72.
47. Ke-Qin Hu1, Huiying Yang2, Ying-Chao Lin2, Karen L Lindsay3 and Allan G Redeker3 Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States Int. J. Med. Sci. 2004 1(2): 92-100 92
48. Bhat SK1, Sachdeva VN, Saleem HI. Profile of viral hepatitis patients in Dakhliya, Oman. Saudi Med J. 2005 May;26(5):819-23.
49. Al-Tawfiq JA1, Anani A. Profile of viral hepatitis A, B, and C in a Saudi Arabian hospital. Med SciMonit. 2008 Jan;14(1):CR52-56.
50. Hitendra GargAshish KumarVishal GargPraveen SharmaBarjesh Chander SharmaShiv Kumar Sarin Clinical profile and predictors of mortality in patients of acute-on-chronic liver failureDOI: http://dx.doi.org/10.1016/j.dld.2011.08.029
51. Jha AK, Nijhawan S, Rai RR, Nepalia S, Jain P, Suchismita A. Etiology, clinical profile, and inhospital mortality of acute-on-chronic liver failure: a prospective study. Indian J Gastroenterol. 2013 Mar;32(2):108-14. doi: 10.1007/s12664-012-0295-9. Epub 2013 Mar 23.
52. Björnsson E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2008; 54 (1): 7-18.
53. Ludwig L, Viggiano TR, McGill DB, Ott BJ. Non alcoholic steato hepatitis. Mayo Clinic experiences with a hitherto unna-med disease. Mayo Clinic Proceedings 1980; 55 (7): 434-8.
54. Bedogni G, Miglioli L, Masutti F et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
55. Yoneda M, Nozaki Y, Endo H et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholicsteatohepatitis (NASH) independent of HFE gene mutation. Digestive Diseases and Sciences 2010; 55 (3): 808-14
56. HemangSuthar, KaushalSuthar, Bhavna Mewada. Clinical profile of cases of alcoholic liver disease Int J Med Sci Public Health. 2013; 2(2): 394-398
57. Onyekwere CA, Ogbera AO, Hameed L Chronic liver disease and hepatic encepha-lopathy: clinical profile and outcomes. Niger J ClinPract. 2011 Apr;14(2):181-5.
58. ZeebaZaka-ur-Rab, Kamlesh Chopra, B.P. Kalra, Indu Sharma Clinico-pathological profile of children with liver disease in Uttaranchal Curr Pediatric Research2008; 12 (1 & 2): 39-41.
59. Tryambak Samanta, Sutapa Ganguly Aetiology, clinical profile and prognostic indicators for children with acute liver failure admitted in a teaching hospital in paediatric gastroenterology
60. Maria Nikolaou John Parissis M.Birhan Yilmaz MarieFrance Seronde Matti Kivikko Said Laribi Catherine Paugam-BurtzLiver function abnormalities, clinical profile, and outcome in acute decomp-ensated heart failureDOI: 332 742-749 First published online: 22 October 2012
61. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V et al.AESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.doi:10.1093/eurheartj/ehs104.
62. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TGet al.2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the Ame-rican College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Soc-iety for Heart and Lung Transplantation. J Am CollCardiol 2009;53:1-90.doi:10.1016/j.jacc.2008.11.013.
63. Ronco C, Haapio M, House AA, Anavekar N, Bellomo RCardiorenal syndrome. J Am Coll Cardiol2008;52:1527-1539. doi:10.1016/j.jacc.2008.07.051.
64. Ronco C,McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM et al Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703-711. doi:10.1093/eurheartj/ehp507.
65. Jessup M, Costanzo MR The cardiorenal syndrome: do we need a change of strategy or a change of tactics? J Am Coll Cardiol 2009;53:597-599. doi:10.1016/j.jacc.2008.11.012.
66. Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 2000;140:111-120. doi:10.1067/mhj.2000.107177.
67. Lau GT, Tan HC, Kritharides LType of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol 2002;90:1405-1409. doi:10.1016/S0002-9149(02)02886-2.
68. Giannini EG, Testa R, Savarino VLiver enzyme alteration: a guide for clinicians. CMAJ 2005;172:367-379.doi:10.1503/cmaj.1040752.
69. Arcidi JM Jr., Moore GW, Hutchins GM Hepatic morphology in cardiac dysfunc-tion: a c linicopathologic study of 1000 subjects at autopsy. Am J Pathol 1981; 104:159-166.
70. Batin P, Wickens M, McEntegart D, Fullwood L, Cowley AJThe importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995;16:1613-1618.
71. Zannad F, Mebazaa A, Juilliere Y, CohenSolal A, Guize L, Alla F, Rouge P et al Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study. Eur J Heart Fail 2006;8:697-705.doi:10.1016/j.ejheart.2006.01.001.
72. Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009;11:170-177. doi:10.1093/eurjhf/hfn031.
73. vanDeursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, VoorsAbnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 2010;16:84-90.doi:10.1016/j.cardfail.2009.08.002.
74. Amarapurkar DN1, Baijal R, Kulshrestha PP, Agal S, Chakraborty MR, Pramanik SS. Profile of hepatitis B e antigen-negative chronic hepatitis B. Indian J Gastroenterol. 2002 May-Jun;21(3):99-101.
75. Maurizia Rossana Brunetto, Filippo Oliveri, Barbara Coco, Gioacchino Leandro, Piero Colombatto, Juliana Monti Gorin, Ferruccio Bonino. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study^ Journal of Hepatology 36 (2002) 263-270
76. Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick, Steven M. Levine, Kevin A. Pokornowski, Ann W. Walsh Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present 0066-4804/07/$08.000 doi:10.1128/AAC.00833-06
77. Donald P. Francis, Stephen C. Hadler, Sumner E. Thompson, James E. Maynard, David G. Ostrow, Norman Altman et al.The Prevention of Hepatitis B with Vaccine: Report of the Centers for Disease Control Multi-Center Efficacy Trial Among Homosexual MenAnn Intern Med. 1982;97(3):362-366. doi:10.7326/0003-4819-97-3-362
78. Uwe Siebert et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity and mortality. BMC Public Health. 2009 Jan 22;9:34.
79. Epidemiology of hepatitis C virus (HCV) infection. Sy T, Jamal MM.Int J Med Sci. 2006;3(2):41-6.
80. Esteban, J.I.S. Sauleda, and J. Quer, The changing epidemiology of hepatitis C virus infection in Europe.J Hepatol, 2008. 48(1): p. 148-62.
81. Occupational Safety and Health Administ-ration. Blood borne pathogens and needle stickprevention. https://www.osha.gov/ SLTC/bloodbornepathogens/recognition.html (Accessed March 25, 2014).
82. Tarantola A, Abiteboul D, Rachline A. Infection risks following accidental exposure to blood or body fluids in health care workers: a review of pathogens transmitted in published cases. Am J Infect Control 2006; 34:367.
83. Kaur P, Gur R, Berry N, Kar P. Etiology of endemic viral hepatitis in urban North India. Maulana Azad Medical College and LokNayak Hospital, New Delhi, India. 2002 Dec;33(4).
84. Estrada JY, Panaligar MH, Ngelangel CA. Hepatitis B virus infection among OPD patients at Jose R Reyes Memorial Medical Centre: A clinical profile. Phil J Microbiol Infect Dis 2001;30(3):94-100.
85. Kumar T. Incidence of cirrhosis caused by Hepatitis B virus in different sex and age groups in Bihar. JMGIMS 2006 Jan;11(i):52-4.
86. Kaur H, John H, Pawar G, Ninon J, Verma V. Spectrum of acute viral hepatitis and its clinical outcome – a study from Ludhiana, Punjab. Indian J Med Sci 2003;57:71.
87. Bahramali G, Sadehizadeh M, OPlejace SA, Alavin SM, Behbanani AB, AdeliA et al. Clinical, virologic and phylogentic features of Hepatitis B infection in Iranian patients. World J Gastroenterol 2008 Sep 21;14(35):5448-53.
88. Paul SB, Sreenivas V, Gultat MS, Medar K, Gupta AK, Mukhopadhyay S, et al. Incidence of Hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care centre in Northern India. Indian Journal of Gastroenterology 2007;26.
89. Holgado GM, Alora BD, Alora AT. Hepatitis B at the Santo Tomas University Hospital. Phil J Microbiol Infect Dis 1983;12(2):121-9.
90. UshaArora, Amit Mann. Prevalence of Hepatitis B virus, Hepatitis C virus, and HIV in patients with chronic liver disease in Amritsar. JIACM 2007;8(1):29-31.
91. Han BH, Lee SY, Koo JY, Park BC. Prevalence of Hepatitis B and C viral markers in patients with Hepatocellular carcinoma in Korea. Journal of Korean Cancer Association 1991 Dec;23(4).
92. Saigal S, Kapoor D, Tandon N, Thakur V, Guptan RC, Agarwal SR, et al High Seroprevalence and Clinical Significance of Hepatitis B and C Infection in Hospitalized Patients with Alcoholic Cirrhosis.Department of Gastroenterology, GB Pant Hospital, New Delhi, India
93. Alam S, Ahmed N, Mustaza G, Alam K, Khan M. Characteristics of treatment naive chronic hepatitis B in Bangladesh: younger population are more affected;HBeAg negative are more affected. Sudi J of Gastroenterol 2008;14(1):15-9.
94. Ayoola A, Aderoju A, Gadour MO, Hegmi M, Hamza MK, Hafeez M, etal.Serological profile of sporadic acute viral Hepatitis in an area of hyperendemic hepatitis B virus infection. Saudi J of Gastroenterol 2001;7(3):95-102.
95. Aminuddin R. Hepatitis B and C virus infection in Ujung Pondong, Indonesia. GastroenterolJpn 1991 Jul;26(3):184-8.
96. Blankson A, Wiredu Ex, Gycei RK, Adjel A, Tettey Y. Seroprevalence of Hepatitis B and C viruses in cirrhosis of liver in Acora, Ghana. Ghana Med J 2005 Dec;39(4):132-7.